Peter C. Friedman, M.D.
Specialist
- Medicare participating
At a glance
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,298
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
NY license 233949
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 1,298
- Services billed
- 5,188
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 1,439 | 970 |
| Test for allergy using skin patch | 960 | 12 |
| Destruction of precancer skin growth, 2-14 growths | 724 | 169 |
| Destruction of skin growth, 1-14 growths | 409 | 307 |
| Destruction of precancer skin growth, 1 growth | 392 | 282 |
| Biopsy of related skin growth, first growth | 264 | 236 |
| Established patient office or other outpatient visit, 10-19 minutes | 227 | 194 |
| Established patient office or other outpatient visit, 30-39 minutes | 219 | 158 |
| New patient office or other outpatient visit, 30-44 minutes | 207 | 207 |
| Injection of drug or substance under skin or into muscle | 91 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Betamethasone Diprop Augmented (betamethasone/propylene glyc) | 172 |
| Triamcinolone Acetonide Other prescribers in New City, NY | 157 |
| Mometasone Furoate Other prescribers in New City, NY | 145 |
| Ketoconazole Other prescribers in New City, NY | 133 |
| Clobetasol Propionate Other prescribers in New City, NY | 128 |
| Dupixent Pen (dupilumab) Other prescribers in New City, NY | 80 |
| Clobetasol Emollient (clobetasol propionate/emoll) | 76 |
| Gentamicin Sulfate Other prescribers in New City, NY | 73 |
| Tacrolimus Other prescribers in New City, NY | 72 |
| Minoxidil Other prescribers in New City, NY | 66 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 27 payments worth $27,908 in total to this clinician.
| Galderma Laboratories, L.P. | $27,395 |
|---|---|
| UCB, Inc. | $209 |
| Incyte Corporation | $169 |
| Leo Pharma Inc. | $87.70 |
| Heartflow, Inc. | $24.98 |
| Arcutis Biotherapeutics, Inc. | $21.88 |
| Compensation for services other than consulting (speaking, faculty) | $20,400 |
|---|---|
| Consulting Fee | $5,950 |
| Food and Beverage | $1,435 |
| Travel and Lodging | $123 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Galderma Laboratories, L.P. Jul 26, 2025 | Consulting Fee NEMLUVIO · DERMATITIS | $5,950 |
| Galderma Laboratories, L.P. Aug 29, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $5,400 |
| Galderma Laboratories, L.P. Nov 21, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $3,600 |
| Galderma Laboratories, L.P. Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $3,600 |
| Galderma Laboratories, L.P. Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $3,600 |
| Galderma Laboratories, L.P. Oct 3, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $3,600 |
| Galderma Laboratories, L.P. Aug 1, 2025 | Compensation for services other than consulting (speaking, faculty) NEMLUVIO · DERMATITIS | $600 |
| Galderma Laboratories, L.P. Sep 5, 2025 | Travel and Lodging NEMLUVIO · DERMATITIS · travel to KINGSTON, NY · in-kind | $106 |
| Galderma Laboratories, L.P. Feb 28, 2025 | Travel and Lodging NEMLUVIO · DERMATITIS · travel to AIRMONT, NY · in-kind | $16.80 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $19,590 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
AbbVie Inc. · Recruiting · NCT06012240 - M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.